Madrigal Pharmaceuticals struck a $2 billion global licensing agreement with CSPC Pharmaceutical Group for SYH-2086, a preclinical oral glucagon-like peptide-1 (GLP-1) receptor agonist. The deal includes $120 million upfront and potential milestone payments. Madrigal plans to combine this novel GLP-1 agonist with its recently approved fatty liver disease drug, Rezdiffra, aiming to enhance therapeutic outcomes for metabolic-associated steatohepatitis (MASH). Clinical development is slated to start in the first half of 2026.